Leukocytoclastic Vasculitis With Eosinophilia in a Patient Receiving Dupilumab Therapy
- PMID: 40530217
- PMCID: PMC12170232
- DOI: 10.7759/cureus.84252
Leukocytoclastic Vasculitis With Eosinophilia in a Patient Receiving Dupilumab Therapy
Abstract
We present the case of a patient with a history of treated hepatitis C virus who was diagnosed with prurigo nodularis and subsequently developed leukocytoclastic vasculitis (LCV) with eosinophilia following the initiation of dupilumab therapy. A 69-year-old African American female with previously treated hepatitis C virus presented with a papular, pruritic skin eruption initially diagnosed as prurigo nodularis. Despite treatment with oral and topical corticosteroids, she experienced no improvement. Physical examination revealed numerous hyperpigmented papules on the extensor surfaces of both upper extremities, without blisters or bullae. After starting on dupilumab, she noted minimal improvement and developed new erythematous papules on the right upper extremity. A punch biopsy performed due to ongoing symptoms showed perivascular and interstitial neutrophils with numerous eosinophils, consistent with LCV with eosinophilia. Dupilumab was discontinued, and topical tacrolimus was initiated. One month later, repeat biopsy was consistent with lichen simplex chronicus, suggesting the persistence of a chronic inflammatory state following the resolution of the initial vasculitis. This patient's findings underscore the importance of recognizing a potential association between dupilumab and the development of eosinophilic conditions in the context of dupilumab therapy. The temporal relationship between the initiation of dupilumab treatment and the onset of eosinophilic LCV suggests a potential association that should be further investigated and should encourage dermatologists to remain cognizant of the development of LCV in the setting of dupilumab therapy.
Keywords: atopic disease; drug-induced eosinophilia; dupilumab dermatologic reaction; eosinophilic dermatosis; leukocytoclastic vasculitis (lcv); prurigo nodularis (pn).
Copyright © 2025, Wandler et al.
Conflict of interest statement
Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures


Similar articles
-
Successful Treatment of Pediatric Atopic Prurigo Nodularis with Dupilumab.Clin Cosmet Investig Dermatol. 2025 Jun 26;18:1609-1613. doi: 10.2147/CCID.S523134. eCollection 2025. Clin Cosmet Investig Dermatol. 2025. PMID: 40589472 Free PMC article.
-
Vancomycin- induced leukocytoclastic vasculitis in a patient with end-stage renal disease: a case report and literature review.Daru. 2025 Mar 12;33(1):13. doi: 10.1007/s40199-025-00559-w. Daru. 2025. PMID: 40072667 Review.
-
A Case of Orbital Inflammation as the Initial Manifestation of Eosinophilic Granulomatosis with Polyangiitis Following Dupilumab administration, Successfully Treated with Mepolizumab.Ocul Immunol Inflamm. 2025 Jul 8:1-3. doi: 10.1080/09273948.2025.2529342. Online ahead of print. Ocul Immunol Inflamm. 2025. PMID: 40627659
-
Psoriasiform Dermatitis: A Peculiar Presentation in the Setting of Staphylococcus aureus Bacteremia and Hepatitis C.Cureus. 2025 May 22;17(5):e84624. doi: 10.7759/cureus.84624. eCollection 2025 May. Cureus. 2025. PMID: 40546556 Free PMC article.
-
Global Delphi consensus on treatment goals for generalized pustular psoriasis.Br J Dermatol. 2025 Mar 18;192(4):706-716. doi: 10.1093/bjd/ljae491. Br J Dermatol. 2025. PMID: 39844356
References
-
- Dupixent FDA package insert. [ Apr; 2025 ]. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s064lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s064lbl.pdf
-
- Eosinophilia induced by blocking the IL-4/IL-13 pathway: potential mechanisms and clinical outcomes. Olaguibel JM, Sastre J, Rodríguez JM, Del Pozo V. J Investig Allergol Clin Immunol. 2022;32:165–180. - PubMed
Publication types
LinkOut - more resources
Full Text Sources